Premium
Assessment of acrylamide exposure in a population subgroup from the European Prospective Investigation into Cancer and Nutrition (EPIC) study
Author(s) -
Vesper Hubert,
Slimani Nadia,
Hallmans Göran,
Tjønneland Anne,
Strömberg Ulf
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1098
Subject(s) - acrylamide , population , epic , european prospective investigation into cancer and nutrition , medicine , demography , veterinary medicine , prospective cohort study , environmental health , chemistry , art , literature , organic chemistry , copolymer , polymer , sociology
Acrylamide is a suspected human carcinogen. The purpose of this cross‐sectional study was to determine the acrylamide exposure in a subgroup of the EPIC study population by measuring hemoglobin adducts of acrylamide (HbAA) and its metabolite glycidamide (HbGA) as biomarkers of acrylamide exposure. These biomarkers were measured by HPLC/MS/MS. The investigated population consists of 510 persons form 9 different European countries: Sweden, Denmark, United Kingdom (UK), The Netherlands, France, Germany, Italy, Greece and Spain. These randomly selected persons where stratified on gender, smoking and centre In the whole population, values ranged between 15–623 pmol/g Hb for HbAA and 8–377 pmol/g Hb for HbGA. HbAA and HbGA values are significantly higher in smokers than in non‐smokers. In non‐smokers, values ranged between 15–177 pmol/g Hb for HbAA and 8–151 pmol/g Hb for HbGA. Significant differences were observed in HbAA and HbGA values between countries. In non‐smokers, highest median HbAA and HbGA values were observed in the group from the UK, and lowest median HbAA and HbGA values were found in the Swedish and Danish group, respectively. In non‐smokers, highest HbAA and HbGA values were observed in the group from Denmark and the UK, respectively. In conclusion, large heterogeneity in acrylamide exposure was reported between the different European countries participating in this cross‐sectional study.